Syndax Stock Based Compensation from 2010 to 2024

SNDX Stock

USD 13.63 0.16 1.16%

Syndax Pharmaceuticals Stock Based Compensation yearly trend continues to be fairly stable with very little volatility. Stock Based Compensation is likely to outpace its year average in 2024. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2012-12-31

Previous Quarter

9.9 M

Current Value

11.9 M

Quarterly Volatility

2.8 M

Yuan Drop

Covid

Check Syndax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syndax Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.4 K, Interest Expense of 197.6 K or Selling General Administrative of 57.1 M, as well as many indicators such as Price To Sales Ratio of 6.97, Dividend Yield of 0.0198 or PTB Ratio of 2.88. Syndax financial statements analysis is a perfect complement when working with Syndax Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Syndax Pharmaceuticals Correlation against competitors.

For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

Latest Syndax Pharmaceuticals' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Syndax Pharmaceuticals over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Syndax Pharmaceuticals' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Syndax Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Syndax Stock Based Compensation Regression Statistics

	Arithmetic Mean	8,811,837
	Geometric Mean	3,306,821
	Coefficient Of Variation	118.01
	Mean Deviation	7,704,449
	Median	5,450,000
	Standard Deviation	10,399,099
	Sample Variance	108.1T
	Range	32.4M
	R-Value	0.87
	Mean Square Error	28.9T
	R-Squared	0.75
	Significance	0.000029
	Slope	2,016,199
	Total Sum of Squares	1514T

Syndax Stock Based Compensation History

	2024	32.5 M
	2023	31 M
	2022	16 M
	2021	13.3 M
	2020	9.1 M
	2019	6 M
	2018	6.2 M

Other Fundumenentals of Syndax Pharmaceuticals

Stock Based Compensation To Revenue

Syndax Pharmaceuticals Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Long Term Debt	Net Receivables	Deferred Long Term Liab	Short Long Term Debt	Property Plant Equipment	Capital Surpluse	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock	Long Term Debt Total
Total Assets		1.0	0.9	-0.93	-0.93	0.88	0.94	0.63	1.0	-0.64	0.98	0.96	0.59	0.6	0.73	0.61	0.78	0.88	0.9	0.72	0.9	0.94	0.89
Total Stockholder Equity	1.0		0.9	-0.93	-0.92	0.87	0.95	0.6	1.0	-0.65	0.98	0.95	0.58	0.62	0.72	0.6	0.78	0.88	0.91	0.71	0.9	0.94	0.89
Current Deferred Revenue	0.9	0.9		-0.82	-0.81	0.82	0.86	0.44	0.89	-0.47	0.88	0.82	0.4	0.68	0.52	0.37	0.84	0.72	0.81	0.85	0.81	0.85	0.92
Net Debt	-0.93	-0.93	-0.82		0.88	-0.92	-0.77	-0.65	-0.93	0.61	-0.91	-0.88	-0.53	-0.3	-0.69	-0.57	-0.72	-0.8	-0.81	-0.79	-0.8	-0.85	-0.91
Retained Earnings	-0.93	-0.92	-0.81	0.88		-0.91	-0.88	-0.66	-0.93	0.72	-0.95	-0.94	-0.71	-0.55	-0.88	-0.77	-0.88	-0.84	-0.76	-0.65	-0.76	-0.88	-0.81
Accounts Payable	0.88	0.87	0.82	-0.92	-0.91		0.74	0.62	0.87	-0.64	0.9	0.86	0.57	0.35	0.75	0.6	0.89	0.73	0.69	0.78	0.68	0.81	0.85
Short Term Investments	0.94	0.95	0.86	-0.77	-0.88	0.74		0.53	0.95	-0.64	0.93	0.92	0.6	0.81	0.71	0.62	0.75	0.87	0.89	0.55	0.89	0.92	0.78
Total Liab	0.63	0.6	0.44	-0.65	-0.66	0.62	0.53		0.63	-0.19	0.65	0.66	0.62	0.17	0.62	0.59	0.47	0.74	0.64	0.42	0.63	0.68	0.62
Total Current Assets	1.0	1.0	0.89	-0.93	-0.93	0.87	0.95	0.63		-0.65	0.98	0.96	0.59	0.6	0.74	0.61	0.77	0.89	0.9	0.7	0.9	0.94	0.89
Short Term Debt	-0.64	-0.65	-0.47	0.61	0.72	-0.64	-0.64	-0.19	-0.65		-0.65	-0.6	-0.42	-0.39	-0.6	-0.68	-0.59	-0.6	-0.53	-0.3	-0.53	-0.62	-0.48
Common Stock	0.98	0.98	0.88	-0.91	-0.95	0.9	0.93	0.65	0.98	-0.65		0.97	0.65	0.6	0.77	0.6	0.83	0.9	0.88	0.68	0.88	0.96	0.87
Net Tangible Assets	0.96	0.95	0.82	-0.88	-0.94	0.86	0.92	0.66	0.96	-0.6	0.97		0.78	0.59	0.86	0.65	0.8	0.88	0.84	0.61	0.84	0.91	0.82
Long Term Debt	0.59	0.58	0.4	-0.53	-0.71	0.57	0.6	0.62	0.59	-0.42	0.65	0.78		0.42	0.88	0.71	0.59	0.72	0.56	0.18	0.55	0.63	0.5
Net Receivables	0.6	0.62	0.68	-0.3	-0.55	0.35	0.81	0.17	0.6	-0.39	0.6	0.59	0.42		0.4	0.38	0.59	0.61	0.66	0.26	0.66	0.66	0.51
Deferred Long Term Liab	0.73	0.72	0.52	-0.69	-0.88	0.75	0.71	0.62	0.74	-0.6	0.77	0.86	0.88	0.4		0.85	0.74	0.69	0.53	0.37	0.52	0.65	0.54
Short Long Term Debt	0.61	0.6	0.37	-0.57	-0.77	0.6	0.62	0.59	0.61	-0.68	0.6	0.65	0.71	0.38	0.85		0.59	0.63	0.48	0.24	0.48	0.56	0.47
Property Plant Equipment	0.78	0.78	0.84	-0.72	-0.88	0.89	0.75	0.47	0.77	-0.59	0.83	0.8	0.59	0.59	0.74	0.59		0.65	0.59	0.7	0.58	0.74	0.76
Capital Surpluse	0.88	0.88	0.72	-0.8	-0.84	0.73	0.87	0.74	0.89	-0.6	0.9	0.88	0.72	0.61	0.69	0.63	0.65		0.94	0.44	0.94	0.97	0.82
Net Invested Capital	0.9	0.91	0.81	-0.81	-0.76	0.69	0.89	0.64	0.9	-0.53	0.88	0.84	0.56	0.66	0.53	0.48	0.59	0.94		0.56	1.0	0.96	0.88
Long Term Investments	0.72	0.71	0.85	-0.79	-0.65	0.78	0.55	0.42	0.7	-0.3	0.68	0.61	0.18	0.26	0.37	0.24	0.7	0.44	0.56		0.54	0.59	0.83
Net Working Capital	0.9	0.9	0.81	-0.8	-0.76	0.68	0.89	0.63	0.9	-0.53	0.88	0.84	0.55	0.66	0.52	0.48	0.58	0.94	1.0	0.54		0.96	0.87
Capital Stock	0.94	0.94	0.85	-0.85	-0.88	0.81	0.92	0.68	0.94	-0.62	0.96	0.91	0.63	0.66	0.65	0.56	0.74	0.97	0.96	0.59	0.96		0.89
Long Term Debt Total	0.89	0.89	0.92	-0.91	-0.81	0.85	0.78	0.62	0.89	-0.48	0.87	0.82	0.5	0.51	0.54	0.47	0.76	0.82	0.88	0.83	0.87	0.89

Click cells to compare fundamentals

About Syndax Pharmaceuticals Financial Statements

Syndax Pharmaceuticals investors use historical fundamental indicators, such as Syndax Pharmaceuticals' Stock Based Compensation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Syndax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Stock Based Compensation	31 M	32.5 M
Stock Based Compensation To Revenue	0.11	0.10

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Syndax Stock Based Compensation from 2010 to 2024

Latest Syndax Pharmaceuticals' Stock Based Compensation Growth Pattern

Syndax Stock Based Compensation Regression Statistics

Syndax Stock Based Compensation History

Other Fundumenentals of Syndax Pharmaceuticals

Syndax Pharmaceuticals Stock Based Compensation component correlations

About Syndax Pharmaceuticals Financial Statements

Also Currently Popular

Additional Tools for Syndax Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY